药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Methylphenobarbital
Iloperidone
The metabolism of Iloperidone can be decreased when combined with Docetaxel.
Methylphenobarbital
Colchicine
The metabolism of Colchicine can be decreased when combined with Docetaxel.
Methylphenobarbital
Cilostazol
The metabolism of Cilostazol can be decreased when combined with Docetaxel.
Methylphenobarbital
Ibrutinib
The metabolism of Ibrutinib can be decreased when combined with Docetaxel.
Methylphenobarbital
Eliglustat
The metabolism of Eliglustat can be decreased when combined with Docetaxel.
Methylphenobarbital
Armodafinil
The metabolism of Docetaxel can be increased when combined with Armodafinil.
Methylphenobarbital
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Docetaxel.
Methylphenobarbital
Peginesatide
The risk or severity of Thrombosis can be increased when Peginesatide is combined with Docetaxel.
Methylphenobarbital
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Docetaxel.
Methylphenobarbital
Roflumilast
Roflumilast may increase the immunosuppressive activities of Docetaxel.
Methylphenobarbital
Belinostat
The risk or severity of adverse effects can be increased when Docetaxel is combined with Belinostat.
Methylphenobarbital
Trilostane
The risk or severity of adverse effects can be increased when Trilostane is combined with Docetaxel.
Methylphenobarbital
Bleselumab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Bleselumab.
Methylphenobarbital
Rozanolixizumab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Rozanolixizumab.
Methylphenobarbital
Risankizumab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Risankizumab.
Methylphenobarbital
Monomethyl fumarate
The risk or severity of adverse effects can be increased when Docetaxel is combined with Monomethyl fumarate.
Methylphenobarbital
Tetrandrine
The risk or severity of adverse effects can be increased when Docetaxel is combined with Tetrandrine.
Methylphenobarbital
Fluclorolone
The risk or severity of adverse effects can be increased when Docetaxel is combined with Fluclorolone.
Methylphenobarbital
Fluperolone
The risk or severity of adverse effects can be increased when Docetaxel is combined with Fluperolone.
Methylphenobarbital
Begelomab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Begelomab.